Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 221 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Aromatase Inhibitor Clinical Trial				Phase IV				0412-14 UO1-GM61373-06, NCT00228956
	Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer				Phase IV				0501-37 NCT00352872
	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis				Phase III, Phase II				20050113 NCT00243685
	Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer				Phase III, Phase II				WHC-MRI-GU-2006-097 NCT00397761
	Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer				Phase III, Phase II				0120070323 NCT00698971
	Letrozole After Tamoxifen in Treating Women With Breast Cancer				Phase III				CAN-NCIC-MA17 CALGB-49805, E-JMA17, EORTC-10983, IBCSG-BIG97-01, NCCTG-JMA17, SWOG-JMA17, JRF-Vor-Int-10, NCCTG-CAN-MA17, SWOG-CAN-MA17, NCT00003140, JMA17, MA17
	Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer				Phase III				IBCSG-2402 BIG-2-02, CALGB-IBCSG-2402, CAN-NCIC-IBCSG-2402, NCCTG-IBCSG-2402, NSABP-IBCSG-2402, SWOG-IBCSG-2402, NABCI-IBCSG-2402, UCLA-0403024-01, EU-20334, IBCSG-24-02, NCT00066690, EUDRACT-2004-000166-13
	Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer				Phase III				SWOG-S0221 S0221, NCT00070564
	Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer				Phase III				IBCSG-27-02 BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
	Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer				Phase III				ID99-146 NCT00038402


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute